DALLAS--(BUSINESS WIRE)--GeneIQ, a molecular diagnostics laboratory that provides COVID-19 testing to facilities and organizations across the country, recently announced the launch of its combination PCR test for viruses SARS-CoV-2 (COVID-19), influenza A (Flu A), influenza B (Flu B), and respiratory syncytial virus (RSV), better known as the common cold. The new multiplex panel builds upon GeneIQ’s current gold standard PCR test. The company’s 4-in-1 test is available for symptomatic individuals via a non-invasive nasal swab.
“Symptoms for COVID-19, the flu and the common cold can be very similar,” said Frank Howard, CEO and founder at GeneIQ. “With the rise of COVID-19 cases and cold and flu season in full swing, we wanted to provide a test that could diagnose which virus you have. COVID, Flu A/B, or the common cold. We saw the value in creating a more efficient test to meet the needs of our clients, giving individuals and physicians the information they need quickly to ensure the right course of treatment.”
The new combo PCR test has the same turnaround time as the stand-alone COVID-19 PCR test, which is about 24 hours. The process involves inserting a non-invasive nasal swab about half an inch into the nasal cavity and rotating it along the anterior membrane of each nostril. It is as effective and accurate as the nasopharyngeal test, but without the pain or discomfort.
GeneIQ has the ability to test up to 10,000 individuals a day and serves more than 500 long-term care facilities, as well as physician medical practices, state and local municipalities, and corporations across North America.
“GeneIQ has been our lab partner since shortly after the outbreak of this pandemic,” said Marilyn Davis, executive director at Signature Pointe, a life care services community in Dallas. “They’ve been amazing to work with and their turnaround time is great. Their team is easy to work with and is always responsive. If I have to go through a pandemic, I’m glad GeneIQ is my partner to help me navigate through it.”
Located in The Colony, Texas, GeneIQ’s state-of-the-art molecular diagnostics laboratory provides a multifaceted testing portfolio. It focuses on Pharmacogenomic testing (PGx) and infectious disease testing for respiratory, urinary, and COVID-19 pathogens. The company created a highly efficient, automated lab process with a paperless, web-based system that provides 24-hour turnaround time for results. The company’s testing methodology accurately identifies with 97% sensitivity if the virus is currently present, and with 99.9% specificity if the virus is not.